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Summary
CD8+ T cells contribute to the control of HIV, but it is not clear whether initial immune responses 
modulate the viral set point. We screened high-risk uninfected women twice a week for plasma 
HIV RNA and identified twelve hyperacute infections. Onset of viremia elicited a massive HIV-
specific CD8+ T cell response, with limited bystander activation of non-HIV memory CD8+ T 
cells. HIV-specific CD8+ T cells secreted little interferon-γ, underwent rapid apoptosis and failed 
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to upregulate the interleukin 7 receptor, known to be important for T cell survival. The rapidity to 
peak CD8+ T cell activation and the absolute magnitude of activation induced by the exponential 
rise in viremia were inversely correlated with set point viremia. These data indicate that rapid, 
high magnitude HIV-induced CD8+ T cell responses are crucial for subsequent immune control of 
acute infection, which has important implications for HIV vaccine design.
Introduction
Human and animal studies of acquired immune deficiency syndrome (AIDS) virus 
infections provide unequivocal evidence that CD8+ T cells contribute to immune 
containment (reviewed in (Walker and McMichael, 2012)). The HIV viral set point is the 
stable viral load that is established after acute infection. In acute HIV infection in humans, 
HIV-specific CD8+ T cell responses, measured by interferon-γ (IFNγ) secretion, appear as 
the viral load is declining to the set point, suggesting that these cells contribute to initial 
viral control (Borrow et al., 1994; Koup et al., 1994). Moreover, depletion of CD8+ T cells 
in acute AIDS virus infection in macaques leads to persistent high-magnitude viremia, 
which declines as these cells reappear (Jin et al., 1999; Schmitz et al., 1999). Viral evolution 
in response to HIV-specific CD8+ T cell responses as the viral set point is reached provides 
further evidence of early immune pressure (Goonetilleke et al., 2009; Liu et al., 2013). The 
viral set point following acute HIV infection is predictive of subsequent disease progression 
(Lyles et al., 2000), suggesting that early responses play a crucial role in the subsequent 
control of viremia, but whether initial immune responses modulate the viral set point has not 
been determined.
Studies of acute HIV infection have largely been conducted as viral load is declining from 
the peak (Appay et al., 2002; Goonetilleke et al., 2009; Liu et al., 2013; Trautmann et al., 
2012; Turnbull et al., 2009), and therefore little is known about the initial phase of the CD8+ 
T cell response. Such studies have been challenging since hyperacute infection, defined here 
as the period between onset of detectable plasma viremia and peak viral load, remains 
poorly characterized due to the difficulty of identifying infections prior to peak viremia. Pre-
peak viral dynamics have been measured in plasma blood donors, but the unavailability of 
cells from that cohort has left questions regarding corresponding T cell dynamics 
unanswered (Freel et al., 2010; Ribeiro et al., 2010). T cell studies performed in the early 
stages of acute HIV infection have shown that antiviral CD8+ T cell responses measured by 
IFN-γ secretion are narrowly directed and of low magnitude (Dalod et al., 1999; Radebe et 
al., 2011; Streeck et al., 2009; Turnbull et al., 2009). This contrasts with the high magnitude 
of CD8+ T cell activation that have been noted during the period from peak viremia to viral 
set point in HIV infection (Appay et al., 2002; Pantaleo et al., 1994), in excess of 
measurements of virus-specific immunity by IFN-γ Enzyme-Linked ImmunoSpot 
ELISPOT). Early T cell activation has been attributed to bystander activation induced by 
HIV (Bangs et al., 2006; Doisne et al., 2004), but studies of TCR repertoire showing 
oligoclonal expansions imply that they could be antigen-specific (Pantaleo et al., 1994; 
Wilson et al., 1998). Indeed, following yellow fever or vaccinia virus immunization, a 
massive activation of virus-specific CD8+ T cells is induced, without appreciable bystander 
activation (Miller et al., 2008). The relatively weak antigen-specific CD8+ T cell responses 
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reported in early HIV infection seem inconsistent with the observed rapid decline in plasma 
viral load (pVL), typically in excess of 10,000 fold. Likewise, although the magnitude of 
initial CD8+ T cell responses to a given epitope is associated with a more rapid time to 
immune escape, relatively weak IFN-γ ELISPOT responses are observed even for 
immunodominant epitopes at the time of rapid viral load decline (Borrow et al., 1997; 
Brumme et al., 2008; Goonetilleke et al., 2009; Liu et al., 2013; Radebe et al., 2014).
In this study, we sought to define the onset, magnitude and evolution of CD8+ T cell 
responses and their relation to viral load dynamics during the period from onset of HIV 
viremia to pVL set point. We established a cohort of young HIV-negative women at very 
high risk of HIV-1 clade C virus infection in KwaZulu-Natal, South Africa, where the 
reported rate of HIV-prevalence in those from 15 to 49 years of age is 27% (Delva and 
Abdool Karim, 2014). This study, termed FRESH, for Females Rising through Education, 
Support and Health, had two interlinked objectives. One was to establish a pathway out of 
the socioeconomic constraints that put women at risk of HIV infection (Kalichman et al., 
2006), by provision of an intensive empowerment, life-skills and job readiness curriculum, 
coupled with HIV prevention education, through classes taken twice a week over the course 
of a year. The second objective was to cryopreserve baseline blood samples, screen each 
participant twice a week by finger-prick plasma HIV RNA testing for evidence of acute HIV 
infection, and examine the relationship between onset of viremia and adaptive CD8+ T cell 
responses. Here we report results on the first 12 subjects identified. Contrary to the notion 
that early T cell responses are low in magnitude, our results indicate that acute HIV 
infection elicits a massive HIV-specific CD8+ T cell response, with limited bystander 
activation of memory CD8+ T cell responses to other pathogens. These expanded cells then 
undergo rapid apoptosis and lack phenotypic markers associated with long-term memory 
development. Importantly, the data show that the magnitude and rapidity of induction of 
activated CD8+ T cells are crucial factors in modulating subsequent immune control.
Results
Analysis of 12 subjects with hyperacute HIV infection demonstrates exponential rise in 
viremia coincident with CD4+ T cell decline
Finger prick blood samples were obtained from high-risk uninfected women twice a week 
for quantitative HIV RNA testing. Twelve subjects were identified with hyperacute 
infection, defined by detection of HIV RNA prior to peak viremia, representing an incidence 
of 7.3 (95% CI=3.8–12.8) per 100 person-years. Of the 11 subjects for whom we could test 
the earliest sample, all were in Fiebig Stage I (Fiebig et al., 2003). The time from enrollment 
in the study to the first detection of viremia ranged from 39–284 days. pVL measurements 
from each of the 12 infected subjects were obtained at 3–6 time points during the rise to 
peak viremia (Fig. 1). The median pVL at first detection was 3.2 log10 (IQR 2.66–4.57) HIV 
RNA copies/ml. The median peak pVL was 7.01 log10 (IQR 6.68–7.66) RNA copies/ml, 
more than 10-fold higher than the median peak pVL of 5.80 log10 observed in plasma 
donors infected with clade B virus (Ribeiro et al., 2010). Despite differences in peak pVL 
compared to plasma donors, the calculated median viral doubling time was 16.4 h 
corresponding to 0.68 days (IQR 0.65–0.78 days) (Table S1), which is comparable to a 
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median doubling time of 0.65 days in plasma donors from a clade B endemic region 
(Ribeiro et al., 2010). R0, the basic reproductive number that defines the number of infected 
cells a single cell gives rise to when target cells are not limiting, ranged from 5.5 to 14.9 
(Table S1). Frequent measurement of peripheral blood CD4 cell counts revealed a rapid 
decline in cell numbers coincident with peak viremia, reaching a nadir that was on average 
37% of the documented pre-infection average value. CD4 cell counts rebounded but always 
to numbers below pre-infection numbers as the viral load set point was achieved (Fig. 1). 
These data demonstrate the feasibility of identifying hyperacute HIV infection, and 
document the exponential rise in acute viremia coincident with the rapid decline in CD4+ T 
cell counts.
The rapidity and magnitude of CD8+ T cell activation correlate with set point viremia
To elucidate the nature of the CD8+ T cell response induced following onset of plasma 
viremia, we analyzed the expression patterns of CD38 and HLA-DR, markers that have been 
used to define T cell activation during the acute phase of viral infections and following 
vaccination (Appay et al., 2002; Doisne et al., 2004; Miller et al., 2008). Both markers had 
low pre-infection cell surface expression, allowing for the unequivocal identification of an 
emerging activated CD8+ T cell population induced by acute HIV infection. Within 1 to 3 
days following onset of plasma viremia, (DFOPV), and prior to peak viremia, CD8+ T cell 
activation was already detectable, ultimately increasing from less than 1% pre-infection to a 
peak as high as 77% (IQR 41.8%–67.4%) of total CD8+ T cells (Fig. 2a, b). Peak activation 
was delayed compared to peak viremia by a median of 2 weeks, reaching maximal values 
approximately 3 weeks after first detection of viremia (Fig. 2c), and then contracting in all 
11 participants evaluated, reaching a quasi-steady state at a median of 80 days (IQR 73–107) 
(Fig. 2b).
The observed differences in the kinetics of peak activation of CD8+ T cells prompted us to 
determine whether the rapidity and magnitude of CD8+ T cell activation correlated with set 
point viremia, a known predictor of subsequent disease progression (Lyles et al., 2000). As 
shown in Fig. 2d, greater time to peak activation positively correlated with higher pVL set 
point (Spearman r=0.7, p=<0.03). In contrast, the frequency of activated (CD38+HLA 
DR+) CD8+ T cells at peak activation inversely correlated with HIV viral set point 
(Spearman r=−0.8, p=0.009) (Fig. 2e). Although CD4 count is a strong predictor of disease 
progression in chronic HIV infection (Phillips and Lundgren, 2006), nadir CD4 counts did 
not correlate with set point pVL (data not shown, Spearman r=0.15, p=0.65). Because pVL 
set point predicts subsequent HIV disease progression (Lyles et al., 2000), these data show 
that the kinetics and magnitude of HIV-induced CD8+ T cell activation in hyperacute 
infection impact subsequent immune control of HIV.
The ability of HIV-specific CD8+ T cells to proliferate is strongly correlated with viral 
control in chronic infection (reviewed in (Migueles and Connors, 2015)). To further define 
the expansion and subsequent contraction of CD8+ T cells in hyperacute infection, we 
measured intracellular markers associated with cellular proliferation and cell survival. Ki67 
is upregulated in cells undergoing division due to recent antigen stimulation (Gerdes et al., 
1984; Hazenberg et al., 2000), whereas the anti-apoptotic protein Bcl-2 is down regulated in 
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effector cells (Grayson et al., 2000). Pre-infection CD8+ T cells from the 11 donors 
evaluated had a resting phenotype that was Ki67negBcl-2high, with only a median of 0.4% 
(IQR 0.1%–0.8%) displaying a cycling phenotype (Ki67high Bcl-2low) (Fig. 3a). Upon HIV 
infection a population of Ki67highBcl-2lowCD8+ T cells rapidly emerged, reaching a median 
of 25.4% (IQR 13.5–33.5%) (Fig. 3b). Peak expression of these markers was delayed by 
approximately one week compared to peak viremia (representative example, Fig. 3c). 
Simultaneous analysis of the expression pattern for the four markers evaluated (CD38, 
HLA-DR, Ki67 and Bcl-2) on CD8+ T cells confirmed that Ki67high and Bcl-2low 
population was a subset of the CD38, HLA-DR double positive population (Fig. 3d). We 
observed a negative relationship between the frequency of Ki67high Bcl2low CD8+ T cells 
and pVL set point (Spearman r= −0.7, p=0.03) (Fig. 3e). These data indicate that the 
activated cells are also undergoing vigorous proliferation, and indicate that CD8+ T cell 
proliferation induced by acute HIV infection is associated with subsequent viral control.
Hyperacute activated CD8+ T cells are HIV-specific
The observed correlation between the kinetics of activated CD8+ T cells and pVL set point 
suggested that these cells might be HIV-specific. HIV-specific CD8+ T cell responses were 
detectable by intracellular cytokine staining (ICS) for IFN-γ production as early as 3 days 
after detection of viremia in some subjects (Fig. S1a), but were weak at peak activation, and 
appeared to increase as activation was decreasing (Fig. S1b). Using IFN-γ ELISPOT to 
determine responses to the entire proteome, we found that five of 9 donors tested had a 
detectable HIV-specific CD8+ T cell response by day 7–10 following the onset of plasma 
viremia, when CD8+ T cell activation was peaking (Fig. S1c) with many of the early 
responses targeting Gag, Pol and Nef (Fig. S1d). Longitudinal analysis revealed the transient 
nature of many of the early responses given that a median of 31% (IQR 11% to 52%) of the 
early responses measurable in the first 30 DFOPV became undetectable at later time points, 
when new responses were arising (Fig. S2).
The above studies measured the ability of CD8+ T cells to produce cytokines in response to 
synthetic HIV peptides, but did not measure the recognition of endogenously processed 
epitopes. To address this, autologous expanded CD4+ T cells were infected with a patient-
derived clade C HIV virus and used to stimulate peripheral blood mononuclear cells 
(PBMCs). Representative data from one subject (Fig. 4a) show that nearly 20% of total 
CD8+ T cells at the time of peak activation mobilized CD107a upon exposure to HIV 
infected cells, compared to a background of 2.9% cells in a pre-infection sample. Incubation 
of CD8+ T cells in interleukin-2 (IL-2) supplemented media for 5 days resulted in an 
average 30-fold increase in antigen-specific IFN-γ production (Fig. 4b) despite negligible ex 
vivo proliferation during the incubation period (Fig. S3). Summary data for 6 donors using 
CD8+ T cells rested in IL-2-supplemented media showed significantly greater CD107a 
expression compared to IFN-γ, TNF-α, and IL-2 responses (Kruskal–Wallis p<0.0001) (Fig. 
4c). Importantly, CD107a expression at peak activation was not significantly different from 
the median frequency of in vivo proliferating cells defined by Ki67high, BCL-2low (p=0.6) 
(Fig. 4d). These results suggest that the majority of proliferating CD8+ T cells were HIV-
specific effector cells with degranulation potential.
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To further define the specificity of activated CD8+ T cells, we used HLA class I tetramers to 
directly stain antigen-specific cells. Despite the limited availability of tetramers, individual 
responses of 10% or greater were detected in three of four subjects evaluated. In subject 208, 
for whom the most tetramers (five) were available, 36% of all CD8+ T cells were HIV-
specific, at a time when 51% of all CD8+ T cells were activated (Fig. 5a). Similarly, 3 
tetramers identified 34% of total CD8+ T cells as HIV-specific in a second subject at a time 
when 50% of CD8+ T cells were activated (Fig. 5b). In a third donor, only 2 HLA-matched 
tetramers were available, but these identified 12% of total CD8+ cells as HIV-specific for a 
sample with 66% activated CD8+ T cells (Fig. 5c). The forth donor did not have detectable 
responses to 4 HIV tetramers tested, but HIV-specific CD8+ T cell responses were clearly 
present, as evidenced by weak IFN-γ ELISPOT responses (donor 309 in fig. S1 and S2), 
suggesting that the tetramers used did not match in vivo epitopes.
The tetramer data indicated much higher frequencies of HIV-specific CD8+ T cells than did 
the IFN-γ ELISPOT assay. Dual staining by tetramer and IFN-γ at peak activation revealed 
that on average only 20% of tetramer+ cells produced measurable amounts of IFN-γ, 
whereas comparative analysis showed that CMV tetramer+ cells secreted significantly more 
IFN-γ (p=0.01) (Fig. 5d and 5e). Given that only a fraction of known epitopes were tested, 
and that over half of the epitopes targeted in acute HIV infection have not been previously 
identified (Liu et al., 2013), these data strongly support the hypothesis that the majority of 
expanded CD8+ T cells observed during the hyperacute phase of the infection are HIV-
specific.
Limited CD8+ T cell bystander activation during acute HIV infection
Having confirmed that a major fraction of activated proliferating cells were HIV-specific by 
tetramer staining, we next investigated whether CD8+ T cell bystander activation might 
account for some of the additional CD8+ T cell activation. Comparative analyses focused on 
cytomegalovirus (CMV), influenza and Epstein-Barr virus (EBV) specific CD8+ T cells in 
four of the acutely infected subjects. For donor 093, 62.6% of HIV-specific tetramer+ cells 
were activated at peak activation, whereas only 25.7% of CMV-specific and 3.1% of 
influenza specific tetramer+ cells were activated (Fig. 6a). Similarly, in donor 102, 76.5% of 
HIV specific cells displayed an activated phenotype, with minimal activation of CMV- and 
EBV-specific CD8+ T cell responses (Fig. 6b). Higher magnitude activation was observed 
for a total of 13 different HIV-specific tetramers tested in 4 study participants compared to 5 
CMV-, 3 influenza- and 3 EBV-specific responses (Kruskal-Wallis p=0.001) (Fig. 6c). 
Together, these data suggest that there was minimal contribution of bystander activation to 
the observed HIV-induced CD8+ T cell expansion.
Marked apoptosis of HIV-specific CD8+ T cells in hyperacute infection
Our data indicate that the majority of the activated CD8+ T cells in hyperacute infection are 
HIV-specific, and that some of the earliest antigen-specific responses do not persist. We 
next investigated if the early massive activation accelerated cell death given that apoptosis is 
intimately linked with short-lived effector cells in the acute phase of a viral infection 
(Badovinac et al., 2002). Consistent with the observed decrease in Bcl-2 expression in 
activated and proliferating CD8+ T cells (Fig. 7a, b), activated cells also expressed high 
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magnitude of CD95 expression, a potent inducer of apoptosis and one of the major effector 
mechanisms of activated CD8+ T cells involved in cell killing (Fig. 7a) (Kagi et al., 1994). 
Additionally, the activated CD8+ T cells failed to up regulate CD127 (Fig. 7c), which is 
important for cell survival during the contraction phase of an acute immune response (Kaech 
et al., 2003; MacPherson et al., 2001). Dual annexin V and propidium iodide (PI) staining 
revealed that CD8+ T cells from peak activation failed to survive overnight incubation 
compared to pre-infection (p=0.02) and post CD8+ T cell activation (p=0.03) samples (Fig. 
7d). No survival defect was observed for CD4+ T cells (Fig. 7e). Tetramer 
immunophenotyping confirmed that HIV-specific cells were selectively more susceptible to 
apoptosis compared to bystander CD8+ T cell responses (Fig. 7f). Combined, these data 
show that newly differentiated effector CD8+ T cells underwent significant contraction 
despite ongoing viremia, consistent with activation induced cell death and failure to 
upregulate the CD127 molecule involved in long term CD8+ T cell memory formation.
Discussion
The relationship between the onset of HIV viremia, adaptive immune responses and 
subsequent viral control has not been well defined, due to difficulty obtaining samples prior 
to and at peak viremia. Here we identified HIV infected subjects at the onset of plasma 
viremia by screening high-risk uninfected women in an area of extremely high incidence of 
infection twice a week. Our results indicated that hyperacute HIV infection defined as the 
period between first detectable and peak plasma viremia, elicited vigorous activation and 
proliferation of CD8+ T cells, with up to 77% of peripheral CD8+ T cells expressing HLA-
DR and CD38. We determined that the majority of these early-activated cells were HIV-
specific, as inferred by their ability to degranulate when stimulated with autologous HIV-
infected CD4+ T cells, by HLA class I tetramer staining, and by lack of appreciable 
bystander activation. Moreover, we showed that this initial robust CD8+ T cell response 
impacted viral control, consistent with what has been observed in SIV rhesus macaque 
immunization models (Hansen et al., 2011; Hel et al., 2002). Overall these data indicated 
that the onset of plasma HIV viremia is markedly immunogenic for HIV-specific CD8+ T 
cell responses that control acute viremia, and that traditional measures of IFN-γ production 
are an inadequate measure of these responses in the acute phase of infection.
A unique aspect of this study was the availability of samples from the time of onset of 
viremia, allowing accurate definition of kinetics and magnitude of CD8+ T cell activation. 
Both the promptness of induction and the peak magnitude of activated CD8+ T cells 
impacted the rate of early virus replication, indicating that these responses have direct 
antiviral function. The ability of these cells to proliferate also impacted pVL set point, 
indicating that the ability to proliferate is critical in acute infection, as has been shown in 
chronic infection (Migueles et al., 2002; Ndhlovu et al., 2013). However, increased 
apoptosis and lack of CD127 expression was observed on the activated CD8+ T cells, 
indicating that impaired long-term memory may contribute to the inability to fully suppress 
the virus despite robust induction of HIV-specific CD8+ T cells elicited by onset of viremia, 
an important focus for future studies. In addition, persistent antigenic exposure may affect 
resolution of CD8+ T cell activation resulting in impaired CD8+ T cell function and faster 
HIV disease progression (Cossarizza et al., 2012; Trautmann et al., 2012).
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Previous studies of CD8+ T cell responses measured by IFN-γ secretion to HIV peptide 
antigens in acute infection have largely focused on the period following peak viremia 
(Appay et al., 2002; Goonetilleke et al., 2009; Liu et al., 2013; Radebe et al., 2014; 
Trautmann et al., 2012; Turnbull et al., 2009). Those studies suggested that the initial CD8+ 
T cell response is weak, as measured by ICS or ELISPOT. Here, availability of pre-infection 
samples and twice weekly sampling allowed us to more precisely define the onset of viremia 
and the evolution of CD8+ T cell responses. By IFN-γ staining we found that responses were 
weak during peak activation, and increased once activation returned to baseline. In contrast, 
the early HIV-specific CD8+ T response was robust by tetramer staining. In one subject for 
whom 5 different tetramers were available, 36% of all CD8+ T cells were HIV-specific. As 
responses to many additional potential HIV epitopes could not be tested due to lack of 
additional epitopes for the class I tetramers used, and lack of any tetramers for four of the 
subject’s class I alleles, these data likely underestimated the magnitude of HIV-specific 
responses. The use of tetramers also enabled us to determine that acute infection was 
associated with impaired IFN-γ production, but this increased following the return of CD8+ 
T cell activation to baseline, consistent with earlier studies (Radebe et al., 2011; Streeck et 
al., 2014; Trautmann et al., 2012). It is conceivable that the aforementioned limitations of 
IFN-γ as readout contributed to the lack of association between breadth or magnitude and 
viral load set point reported in recent acute infection studies (Radebe et al., 2011; Streeck et 
al., 2014). Our data show that the use of autologous infected cells as targets and the use of 
tetramers allowed for a more sensitive estimation of virus-specific CD8+ T cell responses 
during the early phase of the infection. Previous studies in chronic infection show that the 
majority of in vivo primed, circulating HIV-specific CD8+ T cells are discordant for 
cytolysis and cytokine secretion, notably IFN-γ (Kostense et al., 2002; Varadarajan et al., 
2011). Defining the mechanism accounting for the impaired IFN-γ production during acute 
infection will be an important objective of future studies.
In contrast to the robust activation of HIV-specific CD8+ T cells, CD8+ T cells specific for 
pathogens such as CMV, EBV and influenza virus were minimally activated even when a 
very high proportion of total CD8+ T cells displayed an activated phenotype. These data 
suggested that very limited bystander activation was occurring during the acute phase of 
HIV infection, consistent with previous reports in other acute viral infections and following 
immunization (Butz and Bevan, 1998; Miller et al., 2008; Murali-Krishna et al., 1998). The 
modest activation of CMV- and EBV-specific responses, which tend to reactivate during 
acute viral infections, further supports the notion that most of the observed activation is 
antigen-driven rather than cytokine-driven bystander activation.
These studies also provide insight into the fate of the earliest CD8+ T cell responses in acute 
infection. Activated HIV-specific CD8+ T cells expressed CD95, a death receptor that leads 
to programmed cell death, and down-regulated the pro-apoptotic protein Bcl-2, underscoring 
their susceptibility to activation induced cell death. Additionally, even in this very early 
stage of infection HIV-specific CD8+ T cell responses did not upregulate the IL-7 receptor, 
which promotes long-term survival (Kaech et al., 2003). These data confirm previous reports 
in humans and SIV models showing a survival defect and the skewed phenotype with a 
preponderance of pro-apoptotic effector CD8+ T cells in the first few weeks of infection 
(Mueller et al., 2007; Trautmann et al., 2012). Spontaneous cell death coupled with the pro-
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apoptotic phenotype exhibited by early responses suggest that premature cell death may be 
one reason for lack of persistence of early responses and consequently incomplete virus 
suppression. Although immune escape has also been shown to lead to decreases in HIV-
specific CD8+ T cell responses (Liu et al., 2013), this is likely to occur over a more 
protracted time course and be different for different epitopes, suggesting that apoptosis is the 
major driver of the uniform decline in activated CD8+ T cells observed here.
In conclusion, these results show that longitudinal sampling of high risk uninfected persons 
can identify cases of hyperacute infection, allowing for the assessment of the earliest 
interactions between virus and host. Our data indicate that onset of HIV viremia induces 
vigorous CD8+ T cell activation and proliferation, the majority of which is HIV specific but 
would be missed by traditional IFN-γ ELISPOT assays. The more rapidly peak activation is 
achieved, and the greater the peak activation attained, the lower the subsequent viral load set 
point. These data thus indicate that rapid, high magnitude HIV-induced CD8+ T cell 
responses are critical for subsequent immune control of acute infection, and thus have 
important implications for HIV vaccines.
MATERIALS AND METHODS
Study population and blood samples
Subjects were 18–23 year old HIV-negative women at very high risk of HIV-1 clade C 
infection in Durban, South Africa. Blood and female reproductive tract (FRT) samples were 
obtained at pre-infection, and participants attended twice-weekly sessions in which a 
comprehensive empowerment, life skills and HIV prevention curriculum was provided by 
trained counselors. At each twice-weekly visit, finger prick monitoring for plasma HIV 
RNA was performed, with results provided within 24 hours. Upon detection of viremia by 
NucliSens EasyQ v2.0 assay, participants were contacted, health counseling provided, and 
additional blood samples collected. For each donor, a pre-infection sample and serial post-
infection samples were obtained. Studies of the FRT are reported elsewhere (Anahtar et al., 
2015). All the participants provided written informed consent for and the Biomedical 
Research Ethics Committee (BREC) of the University of KwaZulu-Natal and the 
institutional review board of Massachusetts General Hospital approved the study.
Viruses and synthetic viral peptides
Primary HIV clade C virus was prepared according to a previously described protocol 
(Ndung’u et al., 2006). Four hundred and ten overlapping 18-mer consensus clade C peptide 
sequences spanning the entire expressed HIV proteome as well as optimal class I restricted 
epitopes (http://hiv-web.lanl.gov) were synthesized at the MGH Peptide Core Facility on an 
automated peptide synthesizer using F-moc technology.
Flow cytometry analysis of T cell activation and proliferation
Fresh or previously frozen PBMCs were first stained with viability dye for 10 minutes, 
washed and surface stained at room temperature for 20 min. Cells were permeabilized and 
fixed with intracellular staining reagents according to the manufacturer’s instructions (BD 
Bioscience) before intracellular staining with antibodies to Bcl-2 and Ki-67. Samples were 
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then washed before acquisition and analysis on a BD LSRFortessa flow cytometer (BD 
Biosciences). Data analysis was performed using FlowJo software (Treestar).
ELISPOT and ICS staining
ELSPOT assays were performed as described in a matrix system allowing for identification 
of targeted peptides (Kiepiela et al., 2007). Responses were regarded as positive if they had 
at least 3 times the mean number of SFC in the 3 negative control wells; positive responses 
also had be at least 50 SFC/106 PBMCs. For ICS, cells were first stimulated overnight with 
HIV peptides and stained according to the BD Bioscience ICS protocol. ‘Fluorescence 
minus one’ (FMO) staining was used to define the cutoff for positivity.
Tetramer/ICS studies
Stimulated PBMCs were stained with HLA class I-peptide tetrameric complexes for 45 min 
at room temperature, washed in PBS, 0.5 mM EDTA, 1% BSA and surface stained with 
appropriate surface antibodies for 15 min at room temperature in the dark. Cells were then 
permeabilized, fixed and intracellularly stained with IFN-γ, IL-2 and TNF-α and analyzed 
on a BD LSRFortessa flow cytometer.
Generation of CD4+ T cell targets and CD8+ effector T cells
CD4+ T cells were enriched by depleting CD8+ T cells using CD8+ microbeads (Miltenyi 
Biotech) and rested for 4 hours. CD4+ T cells were stimulated with 5μg/ml of CD3+/CD8+ 
bi-specific antibody (Chen et al., 2012) in R10/50 for 72 hours before infection with patient 
isolated clade C viruses for 48 hours. Infection was monitored by flow cytometry after 
surface staining with CD4 antibody and intracellular staining for HIV-Gag (Kc57-FITC, 
Beckman Coulter). CD8+ T cells were kept in R10/50 for 5 days prior to the co-culture 
experiment.
HIV infected cell recognition assay
Freshly isolated or cultured CD8+ T cells were co-cultured with infected or uninfected 
(mock) autologous CD4 T target cells at a 1:1 ratio. Anti CD107a antibody (BD Bioscience) 
and the secretion inhibitor monensin used according to the manufacturer’s instructions were 
added at the beginning of the 12-h stimulation. After overnight incubation, cells were 
surface stained fixed, permeabilized and intracellularly stained with IFN-γ, TNF- α and IL-2 
monoclonal antibodies. Cells were analyzed by flow cytometry and data analysis was 
performed using FlowJo software.
Statistical analyses
Descriptive statistics, Kruskal Wallis tests, Spearman rank-correlation and Mann-Whitney 
tests were performed using GraphPad Prism version 5.0b. All tests were two-tailed and p-
values of p<0.05 were considered significant. Estimates of rates of viral expansion, viral 
decline following peak-viremia and initial rate of CD4 decline were obtained by fitting 
linear mixed-effects models on acute phase data as described before (Ribeiro et al., 2010). 
The fitting was performed using the Statistical Analysis Toolbox in Matlab (Version 
R2014a). Viral load set point was defined as average viral loads measured between 2 to 8 
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months following onset of plasma viremia because this is the interval when viral loads for 
all are study participants reached steady state (Huang et al., 2012).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dynamics of absolute CD4 count and plasma viral loads during hyperacute HIV 
infection
Plasma HIV-1 RNA magnitude (red) and absolute CD4 counts (blue) before HIV infection 
and following onset of detectable plasma viremia in 12 subjects with hyperacute HIV 
infection that were not receiving antiretroviral treatment. See also table S1
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Figure 2. CD8+ T cell activation following onset of plasma viremia
Longitudinal analysis of CD38 and HLA-DR expression on CD8+ cells after HIV infection. 
(a) Representative FACS plots gated on CD8+ cells expressing CD38 and HLA-DR. Days 
following onset of plasma viremia (DFOPV) are indicated (b) Longitudinal dynamics of 
activated (CD38+HLA-DR+) CD8+ cells for 11 donors in whom samples were available for 
analysis. (c) Representative relationship between HIV-induced CD8+ cell activation kinetics 
and contemporaneous viral load. (d) Correlation between time to peak activation and viral 
load setpoint. (e) Correlation between frequency of activated CD8+ cells at peak activation 
and viral load set point. Spearman’s rank correlation was used in (d) and (e).
Ndhlovu et al. Page 16
Immunity. Author manuscript; available in PMC 2016 September 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. CD8+ T cell proliferation and apoptosis following onset of viremia
(a) Representative FACS plots gated on CD8+ cells expressing Ki-67 and Bcl-2. (b) 
Summary data for the longitudinal analysis of proliferating and pro-apoptotic CD8+ cells for 
11 donors evaluated. (c) Representative relationship between Ki67negBcl-2lowCD8+ T cells 
and contemporaneous viral load. (d) CD8+T cell co-expression of CD38, HLA-DR, Ki67 
and Bcl-2. (e) Correlation between peak Ki67negBcl-2lowCD8+ T cells and viral load set 
point. Spearman’s rank correlation was used in (e).
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Figure 4. Hyperacute HIV infection induces strong CD8+ T cell responses with degranulation 
potential
HIV-specific CD8+ T cell responses were measured by ICS after overnight incubation with 
autologous HIV-infected CD4+ cells. Uninfected autologous CD4+ cells co-cultured with 
CD8+ cells were used as a negative control. (a) Representative flow plots demonstrating 
CD107a expression on CD8+ cells. (b) Upper panel shows CD107a expression on ex vivo 
CD8+ cells from 14 DFOPV incubated for 12 hours with HIV infected autologous CD4+ T 
cells. The lower panel shows CD107a expression on CD8+ cells from 14 DFOPV incubated 
in IL-2 containing media for 5 days prior to co-culture with infected autologous CD4+ T 
cells. (c) Proportion of CD8+ cells secreting cytokines following stimulation with HIV 
infected autologous CD4+ cells. Background responses in the uninfected co-culture 
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condition are subtracted. Statistical significance was determined using Mann-Whitney and 
Kruskal Wallis tests. (d) Comparison between proliferating CD8+ T cells and CD107a 
positive cells at peak activation time points (also see supplementary figures). Statistical 
significance was determined using Mann-Whitney test. See also Figure S1, S2 and S3
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Figure 5. Analysis of HIV-specific CD8+ T cell responses during hyperacute HIV infection using 
MHC class I tetramers
PBMCs were stained with MHC class I tetramers specific for HIV and antibodies against 
CD38 and HLA-DR. All plots are gated on CD8+ T cells. Upper panels show frequencies of 
HIV-specific CD8+ T cells for each HIV tetramer tested. Blue dots depict the frequency of 
tetramer+ cells co-expressing CD38 and HLA-DR overlaid on total CD8+ T cells (red dots). 
Data for subjects 208, 079 and 093 are shown in panels (a), (b) and (c), respectively. (d) 
Flow plots show combined tetramer staining and cytokine secretion measured by ICS. 
Representative data for one of the four donors tested are shown. (e) Proportion of HIV-
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specific and CMV-specific tetramer+ cells secreting IFN-γ following optimal peptide 
stimulation of a peak activation sample. Statistical significance was determined using Mann-
Whitney test.
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Figure 6. Assessment of bystander CD8+ T cell activation during hyperacute HIV infection
Intra-donor activation (CD8+ CD38+ HLA-DR+ cells) profiles of HIV, CMV, EBV and 
influenza virus specific (tetramer+) CD8+ T cells. Data for two donors with detectable 
tetramer+ cells specific for three different pathogens are shown in panels (a) and (b). The 
first columns show flow plots gated on tetramer+ cells, the second column shows flow plots 
gated on tetramer+ cells that are double positive for CD38 and HLA-DR (blue dots) overlaid 
on total CD8+ T cells (red dots). (c) Activation data for 13 HIV, 5 CMV, 3 EBV and 3 
influenza specific tetramer+ cells are graphed. Statistical significance was determined using 
Kruskal Wallis test.
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Figure 7. Activation profiles of CD8+ T cells in hyperacute HIV infection
(a) Phenotypic analysis of HIV specific tetramer+ CD8+ cells. The first flow plot is gated on 
tetramer+ cells, the second, third and fourth plots depict tetramer+ cells (blue dots) overlaid 
on total CD8+ cells. Data showing frequencies of tetramer+ cells that are (b) Ki67high, 
BCL2low and (c) CD127high are graphed. Statistical significance was determined using 
Mann-Whitney and Kruskal Wallis tests. (d) Frequencies of dead CD8+ T cells (annexin-V+, 
PI+ CD8+ cells). Statistical significance was determined using Mann-Whitney test. (e) 
Frequencies of dead CD4+ T cells (annexin-V+, PI+ CD4+ cells) after overnight incubation 
in R10. Statistical significance was determined using Mann-Whitney test. (f) Flow 
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cytometric data for two donors showing ex vivo expression of annexin V by HIV tetramer+ 
and CMV tetramer+ cells at peak activation.
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